Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA ...

A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

An AI test boosts cure chances for prostate cancer by predicting who benefits from abiraterone, reducing side effects and ...

Dr. Cheryl Matter shares expert insights into the role physician education can play in ensuring innovative tools reach patients and help improve patient care.

In this pilot trial, acupuncture produced greater reductions in nocturia (waking up 1 or more times to urinate) relative to ...